The mechanism is that CCR3mAb binds to the Fc domain of CCR3 expressed on the surface of mast cells, eosinophils, and other cells via its crystallizable region (Fc), thus blocking the Eotaxin/CCR3 pathway.Subsequently, it inhibits a series of activities downstream of mast cells and eosinophils (differentiation maturation, chemotaxis recruitment, cytokine and inflammatory mediator release and degranulation), thereby achieving the goal of relieving respiratory allergy.Using CCR3 mAb can block the CCR3-Eotaxin axis to relieve allergic-related diseases. The gene discussed is CCR3; the disease is allergic respiratory disease.